Skip to main content
Premium Trial:

Request an Annual Quote

MDRNA Granted Continued Nasdaq Listing; Issues Prospectus to Sell $12.5M in Stock and Warrants

Premium

MDRNA announced this week that the Nasdaq Stock Exchange has granted the company's request to remain listed on its Global Market until Aug. 31, when it must meet the exchange's minimum $10 million stockholder's equity requirement or demonstrate a greater than $50 million market value of listed securities.

"We are pleased that NASDAQ has granted our request to remain on The NASDAQ Global Market," MDRNA President and CEO Michael French said in a statement. "We remain confident that our plan to regain compliance … is achievable well before August 2009."

Also today, the US Securities and Exchange Commission released MDRNA's prospectus to sell 5.25 million shares of its common stock at $2 each, as well as warrants to buy an additional 5.25 million shares at $2.38 per share, directly to "select investors."

On Wednesday, shares of MDRNA closed at $2.11.

According to the filing, the net proceeds of the stock offering are expected to be about $9.5 million. If the warrants are exercised, the net proceeds are expected to be roughly $12.5 million.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.